| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
2,971,000 |
| Market
Cap: |
213.02(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0717 - $0.0717 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Timber Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Co.'s mid to late-stage programs are: TMB-001, a topical formulation of isotretinoin using Co.'s IPEG™ delivery system for the treatment of moderate to severe subtypes of congenital ichthyosis, a group of rare genetic keratinization disorders that lead to dry, thickened, and scaling skin; and TMB-002, a proprietary topical formulation of rapamycin, is being evaluated for the treatment of facial angiofibromas in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-14 |
4 |
S |
$1.27 |
$185,557 |
D/D |
(146,465) |
4,637,517 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-10 |
4 |
S |
$1.26 |
$233,926 |
D/D |
(185,229) |
4,783,982 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-09 |
4 |
S |
$1.27 |
$122,907 |
D/D |
(96,481) |
4,969,211 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-08 |
4 |
S |
$1.29 |
$393,383 |
D/D |
(305,540) |
5,065,692 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-02 |
4 |
S |
$1.26 |
$12,448 |
D/D |
(9,879) |
5,371,232 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-06-01 |
4 |
S |
$1.26 |
$10,952 |
D/D |
(8,670) |
5,381,111 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2021-05-28 |
4 |
S |
$1.27 |
$60,620 |
D/D |
(47,736) |
5,389,781 |
|
- |
|
| Mendelsohn Alan |
Chief Medical Officer |
• – – |
2021-03-03 |
4 |
B |
$2.17 |
$4,314 |
I/I |
1,988 |
1,988 |
1.91 |
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-09-16 |
4 |
S |
$1.03 |
$103,695 |
D/D |
(100,694) |
5,437,517 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-09-15 |
4 |
S |
$1.03 |
$89,550 |
D/D |
(87,060) |
5,538,211 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-09-14 |
4 |
S |
$1.03 |
$469 |
D/D |
(455) |
5,625,271 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-09-11 |
4 |
S |
$1.03 |
$7,710 |
D/D |
(7,483) |
5,625,726 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-09-10 |
4 |
S |
$1.04 |
$34,379 |
D/D |
(32,943) |
5,633,209 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,666,152 |
5,666,152 |
|
- |
|
| Timber Pharmaceuticals Llc |
10% Owner |
– – • |
2020-02-10 |
4 |
S |
$0.01 |
$550 |
D/D |
(55,008) |
2,200,328 |
|
- |
|
| Timber Pharmaceuticals Llc |
10% Owner |
– – • |
2020-02-10 |
4 |
OE |
$0.01 |
$22,553 |
D/D |
2,255,336 |
2,255,336 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-02-10 |
4 |
S |
$0.01 |
$550 |
I/I |
(55,008) |
2,200,328 |
|
- |
|
| Tardimed Sciences Llc |
10% Owner |
– – • |
2020-02-10 |
4 |
OE |
$0.01 |
$22,553 |
I/I |
2,255,336 |
2,255,336 |
|
- |
|
| Vivo Capital Viii, Llc |
10% Owner |
– – • |
2019-06-25 |
4 |
S |
$1.02 |
$334,427 |
I/I |
(327,870) |
317,270 |
|
- |
|
| Krammer Anja B |
Director |
– • – |
2019-01-23 |
4 |
S |
$0.11 |
$12,746 |
D/D |
(115,874) |
1,884,126 |
|
- |
|
| Morlock Stephen |
Director |
– • – |
2018-10-22 |
4 |
S |
$0.18 |
$45,193 |
I/I |
(251,071) |
0 |
|
- |
|
| Morlock Stephen |
Director |
– • – |
2018-10-22 |
4 |
S |
$0.18 |
$39,738 |
D/D |
(220,766) |
0 |
|
- |
|
| Morlock Stephen |
Director |
– • – |
2018-10-19 |
4 |
S |
$0.18 |
$38,536 |
D/D |
(214,091) |
220,766 |
|
- |
|
| Morlock Stephen |
Director |
– • – |
2018-10-18 |
4 |
S |
$0.19 |
$83,429 |
D/D |
(439,099) |
434,857 |
|
- |
|
| Krammer Anja B |
Director |
– • – |
2018-10-12 |
4 |
S |
$0.19 |
$56,525 |
D/D |
(297,500) |
2,000,000 |
|
- |
|
80 Records found
|
|
Page 2 of 4 |
|
|
